US › Healthcare

Capricor Therapeutics Inc (CAPR)

US · Healthcare · Biotechnology

$6.71-7.70%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-40.7M

EPS

$-0.70

EPS estimate

$-0.58

EPS came in at -0.70 against a street estimate of -0.58 — a miss of 20.7%.

Key statistics

Market cap

$400.0M

Forward P/E

78.7

P/B

2.21

Book value

$4.24

EPS (TTM)

$-2.45

52-week high

$40.37

52-week low

$2.96

50-day MA

$7.72

200-day MA

$22.11

Beta

0.61

Analyst view

Analysts rate Capricor Therapeutics Inc a buy (4 buy, 6 hold, 0 sell out of 10) with an average price target of $27.00.

Shareholding

Insiders

9.44%

Institutions

76.29%

Largest institutional holders

Fund	Stake
BlackRock Inc	7.13%
TANG CAPITAL MANAGEMENT LLC	7.05%
Suvretta Capital Management, LLC	7.04%
State Street Corp	5.84%
Vanguard Capital Management, LLC	3.95%
The Goldman Sachs Group Inc	2.71%
RA Capital Management, LLC	2.59%
Boxer Capital Management, LLC	2.40%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Capricor Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.